<DOC>
	<DOC>NCT00712933</DOC>
	<brief_summary>This is a long-term continuation study to provide continuing treatment to subjects with SLE.</brief_summary>
	<brief_title>A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057</brief_title>
	<detailed_description>This trial is a long-term continuation study to provide continuing treatment to subjects with System Lupus Erythematosus (SLE).</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Have completed the HGS 1006C1056 or HGS 1006C1057 protocol through the Week 72 or Week 48 visits, respectively. Have developed any other medical disease or condition that has made the patient unsuitable for this study in the opinion of their physician.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SLE</keyword>
	<keyword>Belimumab</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Lupus</keyword>
	<keyword>Autoimmune Diseases</keyword>
</DOC>